Posts

Neumora to lay off about 35% of staff after navacaprant fails late-stage depression trials

Neumora Therapeutics is laying off about 35% of its workforce after its lead experimental depression drug, navacaprant, failed two Phase 3 trials (KOASTAL-2 and KOASTAL-3) in major depressive disorder. Sources: Neumora discards depression asset, lays off staffers after pair of late ... Neumora Therapeutics scraps depression drug after two late-stage trial failures Neumora scraps depression drug development after repeated trial ... Neumora to lay off 35% of staff after navacaprant goes 0 for 3 in late ... NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials Neumora Ends Depression Drug Programme and Announces ... Neumora Ends Phase 3 KOASTAL Study Of Navacaprant, To Lay Off 35% Of Workforce; Stock Plunges 50% Neumora Therapeutics Reports Data from Phase 3 KOASTAL ... Neumora Therapeutics (NMRA) Stocks News Today - Tickeron.com Neumora (Nasdaq: NMRA) ends navacaprant, cuts 35% of staff and ... Neum...

Lilly oncology chief went from extremely nervous to blown away by new Jaypirca CLL data

FDA Approves Merck’s Welireg–Keytruda Combo as Adjuvant Treatment for Kidney Cancer

Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics-induced CD8 T cell responses and clinical activity

The Oral GLP-1 Tracker: Novo’s Wegovy keeps gaining ground in obesity market

FDA hearing on Amgen's Tavneos will include findings from an independent review

Inside Astellas CEO's 5‑year plan to counter Xtandi's patent cliff

Genentech executes another round of layoffs, with 3 VPs axed

Enliven Therapeutics raises $400M in upsized offering

Novartis tightens bond with Orionis in up to $1.4B molecular glue deal - Biospace, European Biotechnology, LinkedIn, etc.

Takeda's AI‑designed psoriasis pill beats Bristol Myers Squibb's Sotyktu in Phase 3 head‑to‑head trial

Sensorion advances hearing loss gene therapy programs

Kardigan’s $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO